A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)
NCT07734311 on ClinicalTrials.gov · last registry update 2026-08-31
Recruiting now, toward 360 participants. Due to report 31 May 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score. Sponsors move these dates routinely; any movement since this site started watching is listed below. ecnoglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- RECRUITING
- Phase
- P3
- Drug
- ecnoglutide
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Sponsor type
- Industry
- Enrollment
- 360
- Started
- 2026-08-03
- Primary completion
- 2028-05-31 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-08-31 | Status changed | NOT_YET_RECRUITING → RECRUITING |
Primary outcome
Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score
Conditions studied
Knee Osteoarthritis · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the ecnoglutide page for this molecule’s full trial and approval history.